Get started

Elililly

LLY Market Blueprint – From Pullback Base to Profit Zone🎯 LLY Stock Market Heist Plan 🏦💰 | Swing Trade Setup 📊 Asset Overview Eli Lilly and Company (LLY) - NYSE Pharmaceutical Giant | Market Cap Leader 🔍 The Setup: What We're Seeing The chart is screaming opportunity! 🚨 LLY is showing classic bullish pullback behavior with strong accumulation zone activity. We've got: ✅ Accumulation Zone Pressure - Big money is quietly loading up ✅ Weighted Moving Average Breakout & Retest - Technical confirmation ✓ ✅ Bullish Momentum Building - The spring is coiling for the next leg up 🎯 The Thief's Game Plan Entry Strategy: The Layered Approach 🪜 You've got two options here, fellow thieves: Option 1: Simple Entry → Any current price level works if you're confident in the setup Option 2: The Thief's Layered Entry 🧠 This is where we get tactical. Use multiple limit orders to ladder into the position: Layer 1: $780 Layer 2: $800 Layer 3: $820 Layer 4: $840 You can add more layers based on your capital and risk tolerance. This approach averages your entry and reduces timing risk. 🛑 Risk Management: The Escape Hatch Stop Loss: $760 ⚠️ Important Note: This is MY stop loss level based on my risk tolerance and analysis. You are the captain of your own ship! Set your SL based on YOUR risk appetite. Make money, take money - but do it at your own risk. 🎲 💰 Target: The Vault 🏦 Take Profit: $920 Here's the situation: The ATR line is sitting at $920 acting like a police barricade 🚔. This is a strong resistance zone where: Overbought conditions likely Potential trap zone for late entries Natural profit-taking area 🎯 My Advice: When you reach the vault, grab the cash and RUN! Don't get greedy. ⚠️ Another Important Note: This is MY target. You make your own rules. Scale out, hold longer, take profits earlier - whatever fits YOUR trading plan. This is your heist, not mine! 💼 📈 Related Pairs to Watch Keep these on your radar for correlation and broader market context: Healthcare/Pharma Sector: NYSE:JNJ (Johnson & Johnson) - Healthcare bellwether, moves often correlate NYSE:UNH (UnitedHealth Group) - Health sector leader, shows sector strength NYSE:PFE (Pfizer) - Direct pharma competitor, industry sentiment gauge NYSE:ABBV (AbbVie) - Biopharmaceutical peer, similar market dynamics Market Context: AMEX:SPY (S&P 500 ETF) - Overall market direction matters AMEX:XLV (Health Care Select Sector SPDR) - Sector health indicator Key Correlation Points: LLY often leads pharma sector during strong diabetes/obesity drug cycles Watch NYSE:JNJ for defensive rotation signals AMEX:SPY correlation increases during risk-on markets AMEX:XLV breakouts often precede individual pharma stock runs 🎭 The Thief's Philosophy This setup combines patience (layered entries), discipline (clear stop loss), and calculated risk-taking (defined target). We're not gambling - we're executing a well-planned heist with multiple contingencies. The market is the vault. The chart is the blueprint. Your risk management is your getaway car. 🚗💨 Remember: The best thieves know when to strike AND when to walk away. Don't fall in love with a position. Take your profits and live to steal another day! 😎 ✨ If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community! #LLY #EliLilly #SwingTrading #StockMarket #TechnicalAnalysis #NYSE #PharmaStocks #BullishSetup #TradingStrategy #ThiefStyle #LayeredEntry #RiskManagement #PriceAction #MovingAverage #AccumulationZone #HealthcareStocks #TradingIdeas #StockTrading #ChartAnalysis #MarketHeist
NYSE:LLYLong
by The-Thief
"LLY's Bear Market Mode ON | Crash Incoming"“ LLY is gearing up for a sharp correction down to the $35–$17 zone — a critical reset that could flush out weak hands before the next explosive bull run. Stay sharp, this is where big opportunities form. ⚠️ 🔥 Summary: Eli Lilly (LLY) looks ready for a major market reset after completing a historic five-wave climb. This could be the start of a long-term corrective Wave 2 , potentially wiping out years of gains before the next explosive super-cycle takes off. The bull run isn’t over — but it’s taking a serious pause. ⚠️📉 🌊 Wave Theory Outlook LLY’s multi-decade Elliott structure shows a completed Cycle Wave 1 peaking near the 2.618 extension zone around $1029. Historically, such extensions often mark exhaustion. Next comes Wave 2 , which could retrace deep into the $35–$17 zone (the 0.618–0.786 Fibonacci region and prior structural base). Expect a complex W-X-Y pattern , shaking weak hands before a powerful Wave 3 bull expansion later this decade. 📉 Price Action & Smart Money Context The chart shows exhaustion wicks, momentum divergence, and slowing volume — classic signs of distribution . Smart money is likely off-loading near the highs , preparing to reload at discount levels once liquidity below 2020–2022 lows is taken. Expect liquidity sweeps, imbalance fills, and a long-term accumulation base forming near the orange demand zone before the next breakout. 💰 Fundamental Alignment Despite incredible fundamentals — obesity and diabetes drug leadership, global demand growth, and innovation — valuation gravity always returns . A deep correction would align price with sustainable earnings and provide institutional re-entry opportunities at fair value. 🧠 Traders , "the charts are whispering — a major LLY correction is loading. Our projections highlight the $35–$17 zone as the key accumulation region before the next super-cycle. Stay alert, plan your levels, and don’t fight the wave. 🌊📉 Where do you think LLY bottoms out? Share your thoughts below 👇” — Team FIBCOS #LLY #EliLilly #BearMarket #Correction #WaveTheory #SmartMoney #ElliottWave #Fibcos #TechnicalAnalysis #PriceAction #Investing #PharmaStocks #StockMarket #MarketCycle #ChartAnalysis #Bearish #Wave2 #TradingView #StockAlert #MarketReset
NYSE:LLYShort
by fibcos
12
Eli Lilly: Weight-Loss Giant Amid AI Drug Discovery Eli Lilly: Undervalued Weight-Loss Giant Amid AI Drug Discovery and Virginia Jobs Boom Trends? $1050 Target in Sight? Eli Lilly (LLY) shares are trading at $755.39 today, up 0.45% amid analyst upgrades and fresh headlines on its $2.3 billion Virginia manufacturing plant expansion, creating 650 high-paying jobs in Goochland County. This comes as Q2 2025 earnings showcased 36% revenue growth to $11.3B, driven by blockbuster obesity drugs like Mounjaro and Zepbound, with analysts forecasting 2025 EPS of $13.14—up 20% YoY. Just as #AI and #technology explode on X with 17K+ mentions today (fueled by AI video generators and drug discovery hype), and #business trends spotlight corporate expansions like Eli Lilly's Virginia move, LLY's AI-powered R&D pipeline positions it for viral growth in the $100B+ weight-loss market. But with a forward P/E of 28x, is LLY the undervalued pharma powerhouse ready for a rally to $1050, or will patent cliffs and competition temper the upside? Let's break down the fundamentals, SWOT, charts, and setups for September 17, 2025. Fundamental Analysis Eli Lilly's momentum is anchored in its GLP-1 dominance and innovative pipeline, with the Virginia plant bolstering U.S. production amid supply constraints for weight-loss drugs. Analysts expect 2025 revenue of $47.3B (up 18% YoY), powered by approvals for oral obesity pills and oncology breakthroughs like Verzenio. With #AI trends surging on X, LLY's use of machine learning in drug design (e.g., accelerating lung cancer therapies) undervalues its tech edge, trading 18% below fair value per DCF models. However, regulatory hurdles for new GLP-1s could delay peaks if biosimilar competition ramps up. - **Positive:** - Virginia plant announcement drives job creation buzz, aligning with #business trends and signaling supply chain resilience for 20%+ EPS growth. - Q2 beat with $2.9B in Mounjaro sales; AI integrations in R&D tie into today's #AI hype, projecting $100B+ peak sales for obesity franchise. - Broader trends in personalized medicine and #technology (19K mentions) position LLY for 15% annual revenue CAGR amid global demand. - **Negative:** - Patent expirations on key drugs like Humalog loom by 2026, clashing with #AI optimism if innovation lags. - High R&D spend ($10B+ annually) pressures margins if trial delays hit, especially in a sticky inflation environment. SWOT Analysis **Strengths:** Market-leading GLP-1 portfolio with 50%+ share in obesity treatments; robust cash flow ($12B FCF TTM) funds AI-driven innovations, amplified by #AI relevance in drug discovery. **Weaknesses:** Premium valuation at 28x forward P/E amid growth dependency; supply bottlenecks exposed by demand surges, vulnerable in #technology-shifting markets. **Opportunities:** Virginia expansion for 650 jobs taps #business trends; AI for faster trials unlocks $50B+ in new therapies, undervalued at 18% below fair value amid #AI boom. **Threats:** Biosimilar erosion from Novo Nordisk rivals; regulatory scrutiny on weight-loss ads during viral #technology discussions on social media. Technical Analysis On the daily chart, LLY is in a bullish uptrend, coiling in an ascending channel after bouncing from $740 support, with volume rising on plant news and mirroring #AI volatility spikes. The weekly confirms a multi-year bull flag from 2023 lows, now extending higher. Current price: $755.39, with VWAP at $752 as intraday pivot. Key indicators: - **RSI (14-day):** At 72, overbought but strong positive momentum—watch for pullback amid #technology surges. 📈 - **MACD:** Bullish crossover with expanding histogram, signaling acceleration; no divergence yet. ⚠️ - **Moving Averages:** Price above 21-day EMA ($745) and 50-day SMA ($730), golden cross intact for medium-term bull. Support/Resistance: Key support at $740 (recent low and 50-day SMA), resistance at $770 (September high) and $800 (analyst target). Patterns/Momentum: Channel breakout targets $850; strong buy signals. 🟢 Bullish signals: Volume on #business news. 🔴 Bearish risks: RSI overbought could retrace 5% on profit-taking. Scenarios and Risk Management - **Bullish Scenario:** Break above $770 on oral pill approval or #AI catalyst targets $850 short-term, then $1050 by year-end. Buy dips to $740 for entries tied to Virginia jobs hype. - **Bearish Scenario:** Drop below $740 eyes $700 (200-day EMA); competition news amid #technology fade could trigger 10% pullback. - **Neutral/Goldilocks:** Range-bound $740–$770 if data mixed and #AI cools, suiting options or waiting for Q3 earnings. Risk Tips: Use stops 2% below support ($725) to manage volatility. Risk 1-2% per trade. Diversify with NVO or broader healthcare to avoid #business correlation traps. Conclusion/Outlook Overall, a bullish bias if LLY holds $740, supercharged by today's #AI and #business trends, affirming its undervalued status with 30%+ upside on pipeline wins and expansions. But watch FDA updates and Q3 guidance for confirmation—this fits September's healthcare rotation amid viral tech hype. What’s your take? Bullish on LLY amid #AI drug trends or waiting for a dip? Share in the comments!
NYSE:LLYLong
by DCAChampion
Eli Lilly (LLY) – Pharma Giant at a Key Price LevelHi, Eli Lilly & Co. is one of the world’s largest pharmaceutical companies, founded in 1876 and headquartered in Indianapolis. It operates in over 125 countries and is best known for blockbuster treatments in diabetes, obesity, oncology, and immunology. Recent growth has been driven largely by its GLP-1 class drugs Mounjaro and Zepbound, which have quickly become industry leaders in the weight-loss and diabetes markets. Recent Fundamentals (Q2 2025) Revenue: $15.56 B (+38% YoY) - EPS: $6.31 (beat expectations) - Mounjaro sales: $5.2 B - Zepbound sales: $3.38 B - Full-year guidance: Revenue $60–62 B, EPS $21.75–$23.00 - Margins: Gross margin ~82.6%, net margin ~25.9% - Profitability: ROE ~75.5%, ROIC ~29.6% While fundamentals remain strong, the recent Phase III data for the oral weight-loss pill orforglipron came in below expectations, sparking a ~14% drop, the stock’s steepest one-day decline in decades. Analysts have since trimmed long-term sales forecasts for this product. From a valuation perspective, the stock trades at a premium (~41× P/E, ~10.7× P/S), leaving little room for major disappointments. Technicals Technically speaking, the price has arrived in the zone where I’ve been patiently waiting to share it as an idea. This is a good area from where to start building positions if you’re interested. There are quite a few technical confluence factors aligning here, but be ready to grab it also around $500 if the market offers it. Let that be your guide: - If you’re not willing to hold long-term, don’t touch it. - If you’re not willing to buy more at lower prices, don’t touch it. Good luck, Vaido
NYSE:LLYLong
by VaidoVeek
NovoNordisk, possible rotation,safe green buy Zone after confirmNovo Nordisk got slammed after Patrick appeared in the Technical analysis and slammed the Price all the way down to goblintown. After some profit cuts and FUD in the market a possibly rotation is possible. The GLP-1 market is misunderstood. if a rotation is confirmed and some more facts will be shared after lilly earnings today a possible rotation and green buy zone will be confirmed. after new facts and confirmation a High risk/reward oppertunity is possible. Let's all hope patrick will appear back again (maybe after lilly earnings) in the charts and will take everyting upside down. Good luck.
NYSE:NVOLong
by jornwaterlander
ELI LILLY Is starting its next big rally.Eli Lilly (LLY) is about to test its 1W MA50 (blue trend-line) following a rebound just below the 1W MA100 (green trend-line). The latter, has been the ultimate market Support since May 2018 (last time it broke below it). The overall correction since the July 15 2024 High seems like a Bull Flag pattern, no different than all the others after 2018 which only served as healthy rebalancing of an overbought price action. Based on he 1W RSI in particular and the Bullish Divergence it displayed, the current Bull Flag resembles more the March - October 2019 pattern. Both that and the next one reached their 2.0 Fibonacci extensions. As a result, our long-term Target on LLY is just below the 2.0 Fib at $1300. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
2
Eli Lilly Stock Down 10.9% Over Past YearTop or Consolidation? Here's My Take... It's not crystal clear — I can see the case for both. But after years of chart-watching, this doesn't quite look like a top to me: • Lacks symmetry • Had chances to break down, but no real follow-through 🧭 Where are we headed? I think pressure remains, and we could dip toward the 50% retracement of the 2023 move — that’s around 646. 🔁 If we bounce from there, I’ll shift my bias to a recovery and resumption of the long-term uptrend. Disclaimer: The information posted on Trading View is for informative purposes and is not intended to constitute advice in any form, including but not limited to investment, accounting, tax, legal or regulatory advice. The information therefore has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. Opinions expressed are our current opinions as of the date appearing on Trading View only. All illustrations, forecasts or hypothetical data are for illustrative purposes only. The Society of Technical Analysts Ltd does not make representation that the information provided is appropriate for use in all jurisdictions or by all Investors or other potential Investors. Parties are therefore responsible for compliance with applicable local laws and regulations. The Society of Technical Analysts will not be held liable for any loss or damage resulting directly or indirectly from the use of any information on this site.
NYSE:LLY
by The_STA
Can Lilly Redefine Weight Loss Market Leadership?Eli Lilly is rapidly emerging as a dominant force in the burgeoning weight loss drug market, presenting a significant challenge to incumbent leader Novo Nordisk. Lilly has demonstrated remarkable commercial success despite its key therapy, Zepbound (tirzepatide), entering the market well after Novo Nordisk's Wegovy (semaglutide). Zepbound's substantial revenue in 2024 underscores its rapid adoption and strong competitive standing, leading market analysts to project Eli Lilly's obesity drug sales will surpass Novo Nordisk's within the next few years. This swift ascent highlights the impact of a highly effective product in a market with immense unmet demand. The success of Eli Lilly's tirzepatide, the active ingredient in both Zepbound and the diabetes treatment Mounjaro, stems from its dual mechanism targeting GLP-1 and GIP receptors, offering potentially enhanced clinical benefits. The company's market position was further solidified by a recent U.S. federal court ruling that upheld the FDA's decision to remove tirzepatide from the drug shortage list. This legal victory effectively halts compounding pharmacies from producing unauthorized, cheaper versions of Zepbound and Mounjaro, thereby protecting Lilly's market exclusivity and ensuring the integrity of the supply chain for the approved product. Looking ahead, Eli Lilly's pipeline includes the promising oral GLP-1 receptor agonist, orforglipron. Positive Phase 3 trial results indicate its potential as a convenient, non-injectable alternative with comparable efficacy to existing therapies. As a small molecule, orforglipron offers potential advantages in manufacturing scalability and cost, which could significantly expand access globally if approved. Eli Lilly is actively increasing its manufacturing capacity to meet anticipated demand for its incretin therapies, positioning itself to capitalize on the vast and growing global market for weight management solutions.
NYSE:LLYLong
by UDIS_View
Eli Lilly (LLY) Shares Fall Over 15% in MayEli Lilly (LLY) Shares Fall Over 15% in May The share price of Eli Lilly and Company (LLY), the world’s largest pharmaceutical company, has seen a sharp shift in market sentiment: → From its April low to high, LLY shares rose by over 30%; → However, since the start of May, the LLY stock price has dropped more than 15% — the closing price on the last trading day of April was around $895, while today the share is trading near $775. Why Are Eli Lilly (LLY) Shares Falling? The decline can be attributed to three key factors: 1→ Q1 Earnings Report: Although the company reported earnings per share above expectations ($3.34 vs $3.25), investors may have been concerned by significantly higher spending on research and development. 2→ Competitor Partnership: CVS Health’s announcement that it will offer Novo Nordisk’s Wegovy instead of Lilly’s Zepbound added further pressure to LLY shares. 3→ Sector Sentiment: Broader biotech sentiment turned negative following reports that the Trump administration is considering a pricing model that would cap drug prices based on lower rates in other countries. The media is also discussing upcoming decisions from Vinay Prasad, the new head of the FDA division overseeing vaccines and gene therapy. Technical Analysis: Eli Lilly (LLY) Share Chart Key price movements (marked on the chart) justify the formation of a downward channel. On the one hand, bearish sentiment may intensify in light of recent developments. The median line of the channel could act as resistance to any upward movement. On the other hand, bulls may find support around the $765 level — a former resistance point and the boundary between two price gaps. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:LLY
by FXOpen
ELI LILLY: The time to buy and target 1,300 is now.Eli Lilly is neutral on its 1D technical outlook (RSI = 48.409, MACD = -5.160, ADX = 28.927) and this is technically the most efficient level to buy for the long term towards the end of the year, as the price is sitting around its 1W MA50. The macro pattern is a Channel Up starting back in March 2019 and every time this broke under the 1W MA50 (but remained supported above the 1W MA100) and consolidated, it was the most efficient long term buy signal. In 6 years this has only happened 4 times and all those times the 1W RSI hit the 38.750 S1 level. The immediate target of all bullish waves that started after such bottoms, has been the 2.0 Fibonacci extension. Go long, TP = 1,300. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
ELI LILLY ahead of a 1D Golden Cross targeting $1225Last time we looked at Eli Lilly (LLY) 3 months ago (November 21 2024, see chart below), we've identified the bottom of its 5-year Channel Up and issued a strong long-term buy signal: Now we are upgrading our Target as the price action turned out to be very similar to the 2nd half of 2020, at the end of which the company witnessed strong growth. As you can see both 2020 and 2024 patterns have been correction phases in the form of Channel Downs. Even their 1D RSI sequences are similar. A 1D Death Cross paved the way for the bottom soon after and a 1D Golden Cross (Jan 11 2021) confirmed the start of a new phase of growth. The price is now above the 1D MA200 (orange trend-line) and if it continues to replicate 2021, then we expect this to be a Bullish Leg that will target the 1.786 Fibonacci extension. Our long-term Target now goes from $1135 to $1225. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Finally a stock I like...this one is a real dealFinally, an investment idea! (after how much doom and gloom?) — Novo Nordisk. You will all be familiar with Ozempic, the Danish company’s flagship product and the reason so many celebrities, influencers, b listers and regular schmegular Americans are suddenly skinny. I ignored the stock for most of ‘23/24, because it was so expensive. I am still a value investor (for my sins) and I just didn’t see a lot of value there — it was priced in. Imagine my surprise as I was thinking about “megatrends” (vom) for the year ahead — AI, data, 'zempy. Novo stock has fallen 37.80% in the last six months. And you know what that means…that’s a real deal! Why is it a real deal? (Don’t you like booze stocks Eden?) Ozempic is not going away. At this point it is synonymous with weight loss as “Uber” is to ridesharing or Google is to search. Note this data per Barclays, from recently issued rx data in the US — Ozempic script issuance has grown +8.4%, while WeGovy slightly trails it at 7.4% — both owned by Novo. While Eli Lilly also makes a GLP, Novo is still the leader. Strong guidance from management on sales — +16% - 24% — roughly implies revenue of $48bn for ‘25 and $57bn for ‘26…that’s a compounder. America and much of the western world has an obesity problem. There is a clear incentive for governments to underwrite the drug because obesity has a clear social + fiscal cost on society — per UoA, the fiscal cost of obesity in NZ is at least $2bn¹. People have an incentive to use Ozempic, because they are vain. This is a nice hedge against the booze stocks I like so much. Benefit from both sides of the trade — buy booze at low teens multiples; buy Novo and benefit from lower drinking rates as there’s several studies that imply ‘Zempy reduces drinking. I don’t want Ozempic, because I like to live the good life. This does not mean the vast majority of people won’t use Ozempic. At the moment, one in eight Americans have used a GLP. That’s +334mn people. 40% of Americans are obsese. There’s a Lollapalooza effect happening here — a bunch of incentives — vain people, governments wanting less obese people, the various side health benefits of GLPs, etc. I like when a lot of incentives are aligned because you’re relying on psychology rather than projecting numbers on an excel spreadsheet. Novo has sold off recently due to a trial of its CagriSema drug missing expectations. Eyes on the prize, though — current GLPs, which still have plenty of market to saturate. Eli Lilly has traded up in recent times, while Novo has traded down. The two tend to trade in lockstep so the disconnect is an opportunity to buy the world’s leading GLP maker at a good price. Eli Lilly is the closest comp, but it trades at a 38x fwd multiple, while Novo trades at 20x — i.e. an almost 50% multiple discount (see chart). I like that too… Note analyst recs on chart also… This analysis is provided by Eden Bradfeld at BlackBull Research—sign up for their Substack to receive the latest market insights straight to your inbox.
NYSE:NVO
by BlackBull Markets
1
Loss in weight loss Drugs GLP1 Drug producers started 2024 with very strong momentum with Lilly touching nearly a market cap of 1T USD. But since then, the GLP1 manufactures have lost a lot of momentum. Novo Nordisk is at 52 weeks low as shown by the red line. Eli Lilly stock chart also showing bearish engulfing candle. The 20-Day, 50-Day and 100-Day are almost below the 200 Day SMA showing bearish divergence. IN the short to medium term the Price trend looks bearish unless there is a positive catalyst for the stock.
NYSE:LLYShort
by RabishankarBiswal
3
Why Buy LLY?A textbook spike trade... that's why! Every morning the stock market open gives us opening volatility spikes on the first 30 minute bar. Most are noise but when that rare one comes along that fits my rules AND has multiple matching confluences... it's time to "Strike at the Spike!" This setup has going for it: At a 50% Retracement of the recent trend (from November 18 - December 4) At the top of a Gap Level At the Volume Profile Point-of-Control for the last year of price action (see below) With a Spike that my indicator shows >80% ATR Clearance I consider the baseline for a trade; this one is 150% so it definitely fits the rules. I would take a spike if there were only 2 of those matching levels above. Targeting the local high for the first take profit at 834. Here is the Daily chart for just how key this level is: Full disclosure: NYSE:LLY is and has been one of my biggest holdings; having owned the stock for over a decade.
NYSE:LLYLong
by norok
Can Pharma Innovation Rewrite Healthcare's Future?In the rapidly evolving landscape of medical technology, Eli Lilly emerges as a beacon of transformative potential, challenging conventional boundaries of pharmaceutical innovation. With a strategic masterstroke, the company has positioned itself at the forefront of medical breakthroughs, particularly in the revolutionary realm of weight loss and diabetes treatments. The remarkable Zepbound medication stands as a testament to this vision, demonstrating unprecedented efficacy by enabling patients to lose an average of 20.2% body weight - a figure that not only surpasses competitors but also represents a paradigm shift in medical intervention. The company's financial architecture is equally compelling, reflecting a meticulously crafted approach to growth and shareholder value. With a staggering market capitalization of $722 billion, a 27.4% revenue growth, and an impressive 80.9% gross profit margin, Eli Lilly transcends the traditional pharmaceutical business model. Its recent $15 billion share buyback program and consistent 54-year dividend payment history underscore a strategic philosophy that balances aggressive innovation with prudent financial management, creating a blueprint for sustainable corporate success. Beyond financial metrics and breakthrough medications, Eli Lilly represents something more profound: a vision of healthcare's future where technology, research, and human potential converge. The company's $3 billion manufacturing expansion, commitment to oncology research with drugs like Jaypirca, and continuous investment in cutting-edge medical solutions paint a picture of an organization that sees beyond immediate profit - an entity committed to reshaping human health through relentless innovation and scientific excellence. In an era of unprecedented medical challenges, Eli Lilly stands not just as a pharmaceutical company, but as a harbinger of hope, demonstrating how visionary thinking can transform global health landscapes.
NYSE:LLYLong
by MorMedia
ELI LILLY has at least +50% upside from here.Eli Lilly (LLY) has been trading within a 5-year Channel Up and last week closed below its 1W MA50 (blue trend-line) for the first time since the week of March 06 2023. Despite the bearish pressure of this Bearish Leg since July 15 2024, that last 1W MA50 closing was the previous Higher Low at the bottom of the Channel Up. The 1W RSI is on a similar level (just below 40.00) with all previous 4 major bottoms and the common characteristic of all was that the stock broke below the 1W MA50 but managed to keep clear and hold the 1W MA100 (green trend-line), practically the most important Support level of the market. If you want a confirmed buy entry, you might want to wait for yet another Bullish Cross on the 1W MACD (as it happened on all previous bottoms), otherwise this buy opportunity is good to go for at least +58% from the bottom (minimum rise among those 4 Bullish Legs). Our Target is $1135. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
5
ELI LILLY: This consolidation is a buy opportunity.Eli Lilly is neutral on its 1D technical outlook (RSI = 52.880, MACD = 1.910, ADX = 25.797) as well as on 1W as for the past 7 weeks it has turned sideways. This consolidation is taking place half-way through the new bullish wave of the Channel Up that started in early 2023. As you see it is supported by the 1W MA50 and every bullish wave in the beginning was almost at +50% but the latest one was +35%. Consequently we expect a minimum of +46.22% from the bottom and that's what we're aiming for (TP = 1,095). See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry. Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended. The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management. Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality. By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment. As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens. Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes. However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments. In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
NYSE:LLYLong
by MorMedia
ELI LILLY Recovered all losses from its High! What's next?Eli Lilly and Company (LLY) posted a miraculous bullish reversal in the past 2 weeks, recovering yesterday all of the losses of the brutal correction since its July 15 All Time High. Having rebounded on its 1D MA200 (orange trend-line) while the 1D RSI touched the 30.00 oversold barrier for the first time since February 28 2023, we can claim that LLY's Channel Up now sets eyes for its next Higher High. This pattern is best illustrated with the use of the Fibonacci Channel levels. After initially holding the 1.0 Fib as Resistance, the 'ceiling' is now the 1.5 Fib extension, basically has been since September 12 2023. The interesting parameter of this pattern is that every approximately +35.00 to +40.00% rise, the price pulls back or turns sideways (red arc pattern) until it eventually hits the 1D MA50 (blue trend-line). As the stock completes a +35% rise from the bottom, a little above the 1000 mark, we expect it to turn sideways at best. The target after that is $1200, exactly on the 1.0 Fibonacci level, which is still a modest one, considering that the ceiling is now the 1.5 Fib extension, as discussed above. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Is Eli Lilly's Stock in a Bubble or just a Correction?Eli Lilly & Co. (NYSE: NYSE:LLY ) has been a standout performer in the stock market this year, with its stock price surging by around 50%, far outperforming the S&P 500’s 15% rise. This impressive performance has brought the stock to trade at 63 times its projected 2024 earnings of $13.75 per share. This raises a critical question for investors: Is Eli Lilly's stock overvalued, or is there still room for growth? Stellar Growth Driven by Innovative Drugs Eli Lilly's recent surge can be attributed primarily to the high demand for its obesity drug, Zepbound, and its diabetes drug, Mounjaro. These two drugs alone are expected to bring in $50 billion in annual peak sales. The company is currently facing a shortage of Zepbound and plans to invest $9 billion in a new manufacturing facility to meet this demand. Additionally, Eli Lilly’s pipeline is extensive, with several drugs under clinical trials across various therapeutic areas. One notable approval is Donanemab, an Alzheimer's Disease treatment, which could generate $5 billion in peak sales. Other successful drugs, such as Verzenio and Zyprexa, also contribute to the company’s robust revenue growth. Financial Performance and Future Projections Eli Lilly's revenue is projected to grow from $34 billion in 2023 to over $60 billion by 2026, representing an increase of over 75%. The company's earnings are also expected to more than triple during this period. Despite a 12% decline in net income from $6.2 billion in 2020 to $5.2 billion in 2023, mainly due to increased non-operating expenses and acquisitions, the adjusted net income margin is poised for a rebound. In Q1 2024, Eli Lilly ( NYSE:LLY ) reported an adjusted net margin of 26.6%, up over 500 basis points year-over-year. The company’s investments in R&D and product development are starting to pay off, and adjusted earnings are expected to range between $13.50 and $14.00 per share in 2024, more than double the previous year. Considering these projections and expected margin expansions, Eli Lilly’s adjusted EPS could reach $25 by 2027. If the stock price remains constant, the forward P/E multiple would decrease to 34x in 2026. However, investors are betting on the stock price increasing, resulting in a more modest P/E contraction to about 52x. This scenario would imply a 50% growth in Eli Lilly's stock price to approximately $1,300 over the next three years. Risks and Competition Despite the positive outlook, Eli Lilly faces risks, particularly from increasing competition in the obesity drug market. Competitors like Novo Nordisk, Roche, and Amgen are also making strides in weight-loss treatments. However, the obesity drugs market is projected to grow 16-fold to over $100 billion by 2030, with Eli Lilly and Novo Nordisk likely dominating this space. Is Eli Lilly's Stock in a Bubble? The term "bubble" implies a scenario where asset prices are inflated beyond their intrinsic value, often driven by speculation and a belief that prices will never fall. While Eli Lilly’s stock has seen tremendous gains, rising 656% over the past five years compared to the S&P 500’s 78.4% increase, it does not necessarily mean it is in a bubble. Eli Lilly’s rise is backed by strong fundamentals, significant revenue growth, and promising developments in its drug pipeline. Conclusion Eli Lilly’s stock is not just a result of speculative trading; it is supported by solid business performance and growth prospects. While there are competitive risks, the company’s innovative drug portfolio and strategic investments position it well for continued success. Any dip in Eli Lilly’s stock should be seen as a potential investment opportunity, offering robust long-term gains. The next few years will likely see Eli Lilly continue its upward trajectory, driven by market share gains and regulatory approvals.
NYSE:LLY
by DEXWireNews